This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
QIAGEN Strengthens Cancer Research Foothold on New License
by Zacks Equity Research
QIAGEN N.V. (QGEN) has received a worldwide license for biomarkers to be used in identifying patients who may have benefited from immune-oncology (I-O) therapies in cancer treatment.
Myriad Genetics BRACAnalysis CDx in OlympiAD Results Positive
by Zacks Equity Research
Myriad Genetics, Inc. (MYGN), a leading molecular diagnostics and personalized medicine company recently unveiled positive data pertaining to its BRACAnalysis CDx test.
Align Sets Up Manufacturing Center in China, Grows in APAC
by Zacks Equity Research
Align Technology (ALGN) has recently inaugurated a new Invisalign treatment planning facility in Chengdu, China.
Inogen Secures New Direct-to-Consumer Business Facility
by Zacks Equity Research
Inogen, Inc. (INGN) announced that it has secured a new business facility in the Cleveland, OH area.
Abbott Laboratories at 52-Week High on Product Line, Buyouts
by Zacks Equity Research
Share price of IL-based Abbott Laboratories (ABT) scaled a new 52-week high of $46.55 on Jun 2, eventually closing a bit lower at $46.50.
QIAGEN & Bristol-Myers Squibb Partner on Cancer Research
by Zacks Equity Research
QIAGEN N.V. (QGEN) has made significant advancement in the field of cancer research through the use of its revolutionary next-generation sequencing (NGS) technology.
RTI Surgical Now Part of US-Based Manufacturing Initiative
by Zacks Equity Research
RTI Surgical, Inc. (RTIX) recently announced that it is now part of a US public-private Manufacturing initiative, the Advanced Regenerative Manufacturing Institute.
Mead Johnson's Shareholders Approve Reckitt Benckiser Deal
by Zacks Equity Research
Mead Johnson's (MJN) stockholders have okayed the impending merger with Reckitt Benckiser Group.
Hill-Rom Holdings Hits 52-Week High on Solid Product Line
by Zacks Equity Research
Share price of Batesville, IN-based Hill-Rom Holdings, Inc. (HRC) scaled a new 52-week high of $78.51 on Jun 1.
Edwards Lifesciences' TAVR & International Prospects Solid
by Zacks Equity Research
On Jun 2, we issued an updated research report on leading molecular diagnostic company, Edwards Lifesciences Corporation (EW).
Patterson Companies Grapples With Multiple Issues: Dump Now?
by Zacks Equity Research
On Jun 2, we issued an updated research report on St. Paul, MN-based The Patterson Companies (PDCO), a leading distributor of the dental, companion-pet veterinarian and rehabilitation supply markets.
Medtronic Starts PRODIGY Study on Respiratory Compromise
by Zacks Equity Research
Medtronic plc (MDT) recently introduced a new global study on opioid induced respiratory depression (OIRD), a preventable form of respiratory compromise.
Genomic Health to Unveil Oncotype DX Study Results at ASCO
by Zacks Equity Research
Global cancer research company Genomic Health, Inc. (GHDX) will be presenting results from eight Oncotype DX studies at American Society of Clinical Oncology (ASCO) in Chicago.
Align Technology Upgrades iTero Element Intraoral Scanners
by Zacks Equity Research
Based in California, leading dental product maker Align Technology, Inc. (ALGN) recently announced a software upgrade to its iTero Element intraoral scanners.
Becton, Dickinson at 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Share price of Becton, Dickinson and Company (BDX), based in Franklin Lakes, NJ, Becton, scaled a new 52-week high of $188.48 on May 30, eventually closing a bit lower at $188.07.
Baxter International at a 52-Week High on Solid Product Line
by Zacks Equity Research
Share price of Deerfield, IL-based Baxter International Inc. (BAX) scaled a new 52-week high of $59.49 on May 30, eventually closing a bit lower at $59.35.
Intuitive Surgical da Vinci X Surgical System Okayed by FDA
by Zacks Equity Research
Headquartered in Sunnyvale, CA, Intuitive Surgical Inc. (ISRG) recently announced that the da Vinci X Surgical System, an upgrade to its flagship da Vinci Xi surgical platform, has been cleared by the FDA.
Masimo (MASI) O3 Regional Oximetry Device Gets FDA Nod
by Zacks Equity Research
Masimo Corporation (MASI) recently announced the receipt of FDA 510(k) clearance for O3 regional oximetry device.
Inogen (INGN) Hits a 52-Week High on Solid Q1, Upbeat View
by Zacks Equity Research
Shares of Inogen Inc. (INGN) rallied to a new 52-week high of $89.54 on May 26, eventually closing a tad bit lower at $87.93. This represents a strong one-year return of about 84.6%, much better than the S&P 500's return of roughly 9.7%.
Implied Volatility Surging for Accelerate Diagnostics (AXDX) Stock Options
by Zacks Equity Research
Options traders are pricing in a big move for Accelerate Diagnostics (AXDX) shares as it has huge implied volatility.
Is the Options Market Predicting a Spike in Accelerate Diagnostics (AXDX) Stock?
by Zacks Equity Research
Options traders are pricing in a big move for Accelerate Diagnostics (AXDX) shares as it has huge implied volatility.
Accelerate Diagnostics (AXDX) Looks Good: Stock Up 7.5%
by Zacks Equity Research
Accelerate Diagnostics, Inc. (AXDX) rose above 7% in the last trading session.